Cervical dysplasia associated with the use of natalizumab.


N O V E M B E R 2 0 1 3 , V O l . 7 1 , N O 9 © Van Zuiden Communications B.V. All rights reserved. Dear editor, Natalizumab is a monoclonal antibody against anti-α4integrin, which was registered in the Netherlands in June 2006. It is indicated for severe and highly active relapsingremitting multiple sclerosis (MS) in adult patients. In the product… (More)


Cite this paper

@article{Rolfes2013CervicalDA, title={Cervical dysplasia associated with the use of natalizumab.}, author={Ludger Rolfes and Bianca Lokhorst and Johnny P A Samijn and Eug{\`e}ne P. van Puijenbroek}, journal={The Netherlands journal of medicine}, year={2013}, volume={71 9}, pages={494-5} }